We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals
ANIP

126 hedge funds and large institutions have $391M invested in ANI Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 33 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 33

32% more call options, than puts

Call options by funds: $905K | Put options by funds: $688K

18% more capital invested

Capital invested by funds: $330M → $391M (+$61M)

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

0% more funds holding

Funds holding: 126 → 126 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.18% less ownership

Funds ownership: 58.92% → 58.74% (-0.18%)

Holders
126
Holders Change
–
Holders Change %
0%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
46
Reduced
33
Closed
18
Calls
$905K
Puts
$688K
Net Calls
+$217K
Net Calls Change
+$1.21M

Top Buyers

1
RCMNY
Rubric Capital Management (New York)
New York
+$3.35M
2
BlackRock
BlackRock
New York
+$2.2M
3
ACM
AIGH Capital Management
Maryland
+$1.64M
4
SSA
Schonfeld Strategic Advisors
New York
+$1.5M
5
RCAMU
Rothschild & Co Asset Management US
Connecticut
+$1.31M

Top Sellers

1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$4.47M
2
TCM
Tang Capital Management
California
-$3.21M
3
SCM
Sio Capital Management
New York
-$1.29M
4
LSV Asset Management
LSV Asset Management
Illinois
-$1.14M
5
JCIA
Jackson Creek Investment Advisors
Colorado
-$1.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
126
Tang Capital Management
California
– -$3.21M -100,000 Closed
SCM
127
Sio Capital Management
New York
– -$1.29M -40,000 Closed
LSV Asset Management
128
LSV Asset Management
Illinois
– -$1.14M -35,300 Closed
JCIA
129
Jackson Creek Investment Advisors
Colorado
– -$1.03M -32,024 Closed
Victory Capital Management
130
Victory Capital Management
Texas
– -$632K -19,665 Closed
FDCDDQ
131
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$572K -17,800 Closed
Susquehanna International Group
132
Susquehanna International Group
Pennsylvania
– -$618K -16,465 Closed
CCM
133
Cullen Capital Management
New York
– -$441K -13,709 Closed
E
134
Ergoteles
New York
– -$369K -11,484 Closed
CSS
135
Cubist Systematic Strategies
Connecticut
– -$281K -8,751 Closed
MOACM
136
Mutual of America Capital Management
New York
– -$77K -2,401 Closed
ACM
137
Aquatic Capital Management
Illinois
– -$35K -1,100 Closed
PHK
138
Point72 Hong Kong
Hong Kong
– -$13K -402 Closed
TWA
139
TCI Wealth Advisors
Arizona
– -$4K -113 Closed
Federated Hermes
140
Federated Hermes
Pennsylvania
– -$1K -8 Closed
Carson Wealth (CWM LLC)
141
Carson Wealth (CWM LLC)
Nebraska
– +$113 +3 New
2 3 4 5
6

ANIP Hedge Fund Activity: Q4 2022 in Review

126 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2022, worth a combined $391M — up 18% from $330M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ANIP positions and 18 closed out — a net gain of 1 holder — while 46 added to existing stakes and 33 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $3.35M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $4.47M sold.

  • 126 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $391M of ANI Pharmaceuticals stock for Q4 2022, up 18% quarter-over-quarter.
  • 19 funds opened new ANI Pharmaceuticals positions in Q4 2022 and 18 closed out, a net change of +1 holder.
  • The largest ANI Pharmaceuticals buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $3.35M added.
  • The largest ANI Pharmaceuticals seller in Q4 2022 was Balyasny Asset Management, an estimated $4.47M sold.

Based on aggregated 13F filings for Q4 2022.